What does Latigo Biotherapeutics, Inc. do?
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor…
What is Latigo Biotherapeutics, Inc.'s P/E and P/B ratio?
Latigo Biotherapeutics, Inc. has a P/E ratio of -6.6 and a P/B ratio of -3.98.
What is Latigo Biotherapeutics, Inc.'s debt-to-equity ratio?
Latigo Biotherapeutics, Inc. has a debt-to-equity ratio of 2.50.
How much does Latigo Biotherapeutics, Inc. owe compared with what it owns?
Latigo Biotherapeutics, Inc. owes $5.26 for every $1 it owns (balance sheet Jun 2026), which means it owes more than it owns.
What is Latigo Biotherapeutics, Inc.'s Positivity rank?
Latigo Biotherapeutics, Inc. is ranked #6,533 of 6,774 companies globally and #3,781 of 4,000 in United States on PositoAI, with a Positivity Score of -23,492.
Does Latigo Biotherapeutics, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Latigo Biotherapeutics, Inc..
Where can I read the latest news about Latigo Biotherapeutics, Inc.?
Recent headlines about Latigo Biotherapeutics, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Latigo Biotherapeutics, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Latigo Biotherapeutics, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.